At the Crossroads of Local and Systemic Treatment of Operable Non–Small Cell Lung Cancer
Mené sur 27 patients atteints d'un cancer du poumon non à petites cellules de stade I à IIIA et présentant des mutations au niveau du gène EGFR, cet essai multicentrique de phase II évalue l'efficacité, du point de vue du taux de réponse pathologique, de l'osimertinib en traitement néoadjuvant
Over the past decade, we have witnessed renewed interest in neoadjuvant, perioperative, or adjuvant management strategies of operable non–small cell lung cancer (NSCLC). This is a predictable consequence of more effective systemic therapies for advanced NSCLC, which have changed the landscape of thoracic oncology. Unprecedented improvements have been observed with immunotherapies and targeted therapies, the latter of which are limited to specific, oncogene-addicted subsets of patients with distinct disease biology and typically high response rates.